Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Sezary Syndrome 1Sarcoma 1Rectal Neoplasms 1Paget Disease, Extramammary 1Mycosis Fungoides 1Muir-Torre Syndrome 1Microcystic adnexal carcinoma 1Melanoma 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, T-Cell 1Lymphoma, Large-Cell, Anaplastic 1Liposarcoma 1Leiomyosarcoma 1Histiocytoma, Malignant Fibrous 1Eccrine Porocarcinoma 1Carcinoma, Signet Ring Cell 1Carcinoma, Merkel Cell 1Carcinoma, Basosquamous 1Carcinoma, Basal Cell 1Adenocarcinoma, Papillary 1

Interventions

Doxorubicin 4Specimen Handling 3Radiotherapy 3Biopsy 3pazopanib 2Temozolomide 2Sorafenib 2Radiation 2Magnetic Resonance Spectroscopy 2Ifosfamide 2talimogene laherparepvec 1saracatinib 1sapanisertib 1rubitecan 1romidepsin 1peposertib 1liposomal doxorubicin 1cixutumumab 1abemaciclib 1Thalidomide 1Nivolumab 1Molecular Diagnostic Techniques 1Microarray Analysis 1MLN 8237 1Ipilimumab 1HhAntag691 1Gemcitabine 1Etoposide 1Docetaxel 1Diathermy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Leiomyosarcoma × talimogene laherparepvec × Clear all
NCT02923778 2026-05-13

Talimogene Laherparepvec and Radiation Therapy in Treating Patients With Newly Diagnosed Soft Tissue Sarcoma That Can Be Removed by Surgery

National Cancer Institute (NCI)

Phase 2 Active not recruiting
40 enrolled
Sarcoma

Leiomyosarcoma, Liposarcoma, Sarcoma, Histiocytoma, Malignant Fibrous

Data powered by HemOnc (CC BY 4.0) Colophon âš¡